AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

TARA · NASDAQ · Biotechnology

Protara Therapeutics

Develops investigational therapies for cancer, lymphatic malformations, and patients receiving parenteral support.

$3.82

After-hours close+0.01 (+0.26%)

At close$3.81(−4.51%)

Something off on this page? Send us feedback.

Profile

Protara Therapeutics, Inc.TARAHealth Care

Develops TARA-002 for non-muscle-invasive bladder cancer and lymphatic malformations, alongside IV Choline Chloride for patients receiving parenteral support. The clinical-stage company has reported no product revenue.

Advances two investigational programs for cancer, rare-disease, and parenteral-support settings. Its portfolio consists of TARA-002 and IV Choline Chloride. Both programs remain investigational.

TARA-002 is a cell-based therapy in development for non-muscle-invasive bladder cancer and lymphatic malformations. IV Choline Chloride is being developed for patients receiving parenteral support.

Its current operating business entered the public market through a reverse merger after private ArTara merged with Proteon and is headquartered in New York. The company has reported no revenue since inception and says additional capital is needed to fully realize its plans.

Company facts

CEOJesse Shefferman

ListedJan 10, 2020

ExchangeNASDAQ

HeadquartersNew York, NY

CountryUnited States

Employees51

CIK0001359931

ISINUS74365U1079

Key statistics

Market cap$214.7M

EPS (ttm)−$1.36

P/E (ttm)−2.81

ROE-41.7%

P/B1.44

P/S0.00

Dividend yield—

Beta1.04vs XLV 0.97

Year to date −29.2% · Average volume (30d) 375.3K

Analysts

Price target, next 12 months$12.00+214.1%Median of 6 analysts · vs the Aug 28 close

ConsensusBuy6 of 6 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $3.82

High$12.00+214.1%

Median$12.00+214.1%

Low$12.00+214.1%

12 months agoNowIn 12 months

Latest analyst notes

No analyst notes in the last 24 months.

Earnings

EPS

Estimate−$0.36

ReportedDue Nov 9, 2026

Revenue

Estimate—

ReportedDue Nov 9, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 11, 2026Q2 FY26	−$0.33	−$0.36	−10.5%	—	$180.0K	—	−4.87%
May 13, 2026Q1 FY26	−$0.36	−$0.31	+13.9%	—	—	—	+1.92%
Mar 10, 2026Q4 FY25	−$0.32	−$0.37	−15.6%	—	—	—	−1.93%
Nov 10, 2025Q3 FY25	−$0.39	−$0.31	+20.5%	—	—	—	+18.32%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$0	$0	$0	$0	$0	$0
Gross profit	$0	$0	$0	$0	−$90.0K	$0
Operating income	−$14.1M	−$16.6M	−$14.8M	−$19.1M	−$19.6M	−$23.3M
Net income	−$11.9M	−$15.0M	−$13.3M	−$17.3M	−$17.8M	−$21.7M
Diluted EPS	−$0.29	−$0.35	−$0.31	−$0.38	−$0.31	−$0.36
Gross margin	—	—	—	—	—	—
Operating margin	—	—	—	—	—	—

Fiscal years (4-quarter sums)FY21 $0 · FY22 $0 · FY23 $0 · FY24 $0 · FY25 $0

Balance sheet, Jun 30, 2026Cash & short-term investments $17.1M · Total debt $2.7M · Total assets $176.1M · Shareholders' equity $161.3M

Dividends

No dividends on record.

Ownership

Institutions 82.27%46.24M sharesInsiders 1.95%1.10M sharesOther 15.78%8.86M shares

Shares outstanding 56.20M · Float 49.16M · 87.5% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Janus Henderson Group PLC	5.21M	9.60%	13G	May 15, 2026
Jupiter Topco LLC	4.70M	8.36%	13F	Aug 14, 2026
BlackRock, Inc.	3.66M	6.52%	13F	Aug 7, 2026
Millennium Management LLC	3.10M	5.52%	13F	Aug 14, 2026
Velan Capital Investment Management LP	2.84M	5.06%	13F	Aug 14, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Jun 29, 2026	Jesse Shefferman	director, officer: CEO and President	−215,687	$4.09
Apr 8, 2026	Jacqueline Zummo	officer: Chief R&D Officer	−1,134	$5.40
Apr 1, 2026	Jacqueline Zummo	officer: Chief R&D Officer	−22,598	$5.26